1. Scrip
  2. >>Business

Humanigen Data Show Success In High-Risk COVID-19 Population

Lenzilumab Heads To FDA

 
• By Alaric DeArment

Phase III results show benefit in cytokine-release syndrome, while other drugs for treating patients hospitalized with COVID-19 have produced mixed results.

Corona patient
Humanigen plans to seek an EUA for lenzilumab in patients hospitalized with COVID-19. • Source: Shutterstock

Humanigen, Inc. has the chance to meet a key area of medical need in the treatment of COVID-19 with new Phase III data in a population at high risk of progressing to mechanical ventilation or death, where other companies have often met failure.

The Burlingame, CA-based company reported on 29 March positive topline results from its Phase III study of the granulocyte macrophage colony-stimulating factor (GM-CSF)-targeting antibody lenzilumab in patients hospitalized with COVID-19....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.